Mumbai, July 31 -- Profit before tax (PBT) stood at Rs 271.61 crore in Q1 FY26, rising 13.25% from the Rs 239.84 crore recorded in Q1 FY25.

In Q1 FY26, operating EBITDA stood at Rs 330 crore, up 13%, compared with Rs 292 crore posted in the same quarter last year. Operating EBITDA margin stood at 30.2% in Q1 FY26 as against 29% in Q1 FY25.

Nikhil Chopra, CEO and whole-time director of JB Pharma, stated, "JB continues to be the fastest-growing domestic pharma company amongst the top 25 organizations as per IQVIA MAT Jun'25 data. The domestic business recorded approximately 14% value growth. This was driven by acute and chronic segments, including our ophthalmology portfolio.

Our major brands & their franchises are also performing well. ...